Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Liquid paraffin light
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · 1967–2026
Showing the 50 most relevant studies, sorted by most relevant.
Rodríguez Sánchez DI, Öztürk SA, Maxouri O, et al.
2026
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Genetic Heterogeneity
BackgroundActivating epidermal growth factor receptor (EGFR) mutations are key drivers in non-small cell lung cancer (NSCLC) and other solid tumours, predicting responses to tyrosine kinase inhibitors (TKIs). Tumour heterogeneity alongside sampling and technical factors may contribute to discordant EGFR status across biopsies, complicating treatment decisions. However, systematic evidence on prevalence and drivers of discordance remains limited.MethodsThis systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in PROSPERO (CRD42024615727). MEDLINE, Embase, and Scopus (2004-2024) were searched for studies reporting EGFR mutation discordance in adult solid tumours. Eligible studies compared primary and metastatic tumours (tissue-tissue), tissue and liquid biopsies (tissue-liquid), or different liquid biopsies. Data extraction and QUADAS-2 risk of bias assessment were performed independently. Discordance proportions were analysed on the logit scale with Haldane-Anscombe correction when needed. Random-effects meta-analysis was conducted using the Paule-Mandel estimator with Hartung-Knapp-Sidik-Jonkman confidence intervals. Subgroup analyses and meta-regression were used to estimate pooled discordance and explore potential predictors.ResultsA total of 154 studies (15,560 patients) predominantly involving NSCLC were included. The pooled discordance rate was 16.1% (95% confidence interval 14.2-18.2). Rates were similar for tissue-tissue (16.8%) and tissue-liquid (15.5%), but higher for liquid-liquid (34.0%). Plasma was the most-studied liquid source (16.5%), while cerebrospinal fluid showed the highest discordance (35.5%). Prior TKI exposure was associated with higher discordance (25.8%) compared with treatment-naive patients (14.6%; p = 0.003). Patients who later developed resistance also had higher baseline discordance (21.0% vs 15.0%; p = 0.042). Discordance varied by metastatic site, from 15.1% in lymph nodes to 17.9% in brain/central nervous system. Meta-regression identified TKI exposure, resistance, and mutation prevalence as predictors.ConclusionsEGFR mutation discordance is common and clinically relevant, particularly in NSCLC, but varies substantially by sampling strategy, biofluid, treatment context, and metastatic site. Given the high between-study heterogeneity and the predominance of NSCLC and Asian cohorts, pooled estimates should be interpreted as descriptive summaries rather than universally generalisable benchmarks. These findings support integrated and context-aware sampling strategies for EGFR-targeted therapy and resistance monitoring.
Abstract licence: CC BY-NC
D. J. Safarik, R. Eldridge
Industrial & Engineering Chemistry Research, 1998
Rami Faiz, Kang Li
Chemical Engineering Science, 2012
Hai-Yan Wu, Song-tai Li, Yao-wen Shao, et al.
Chemical Engineering Journal, 2020
Haizhong Wang, Qi-Ming Lu, Cheng-Feng Ye, et al.
Wear, 2004
Xiebing Wang, Wan-Wan Li, Kang Sun
Journal of Materials Chemistry, 2011
Álvarez F, Arena M, Auteri D, et al.
2026
Guo H, Hu B, Shan H, et al.
2026
The global population explosion and accelerated industrialization have led to an increasing shortage of fossil fuels and environmental contamination, underscoring the urgent need to develop innovative energy storage technologies to improve energy utilization efficiency. As pivotal components in thermal energy storage (TES) systems, phase change materials (PCMs) enable spatiotemporal matching between thermal energy supply and demand through latent heat absorption and release during phase transitions. Organic PCMs are considered ideal candidates for thermal energy storage due to their high energy storage density, stable phase transition temperature, low supercooling, and negligible phase separation. However, inherent drawbacks such as low thermal conductivity, liquid leakage, limited light absorption, and lack of functionality have hindered their widespread application in advanced thermal management systems. Herein, we systematically summarize cutting-edge functionalization strategies for PCMs, progressing from conventional methods like thermal conductive particle blending and microencapsulation to the emerging design of 3D porous thermally conductive skeletons, including metal foams, boron nitride aerogels, carbon-based aerogels, and MXene aerogels. These frameworks not only enhance thermal transport via continuous conductive pathways and impart shape stability through capillary encapsulation but also, when integrated with photo-thermal, electro-thermal, and magneto-thermal conversion properties, enable broad applications in solar photo-thermal/photo-thermo-electric conversion, thermal management of electronics and batteries, building efficiency, and wearable thermal regulation. The review further addresses current challenges and future directions, highlighting scalable 3D framework fabrication, the shift to active thermal management, and innovative applications beyond conventional domains. By establishing a microstructure-property-application correlation, this work provides valuable insights for developing next-generation high-performance multifunctional phase change composites.
Abstract licence: CC BY
S. Ilyin, M. Arinina, M. Polyakova, et al.
Fuel, 2016
Zhi-Gang Wang, B. Hsiao, E. Sirota, et al.
Macromolecules, 2000
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.